高级检索
当前位置: 首页 > 详情页

Bi-directional roles of IRF-1 on autophagy diminish its prognostic value as compared with Ki67 in liver transplantation for hepatocellular carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]First Central Clinical College, Tianjin Medical University, Tianjin, P. R. China [2]Department of Transplantation, Tianjin First Central Hospital, Tianjin, P. R. China [3]Tianjin Key Laboratory of Organ Transplantation, Tianjin, P. R. China [4]Laboratory of Immunology and Inflammation, Tianjin Medical University, Tianjin, P. R. China [5]Beijing Friendship Hospital, China Capital Medical University, Beijing, P. R. China
出处:

关键词: IRF-1 Ki-67 autophagy HCC liver transplantation

摘要:
The prognostic values of IRF-1 and Ki-67 for liver transplantation (LT) of hepatocellular carcinoma (HCC) were investigated, as well as the mechanisms of IRF-1 in tumor suppression. Adult orthotropic liver transplantation cases (N = 127) were involved in the analysis. A significant decreased recurrence free survival (RFS) was found in the Ki-67 positive groups. Ki-67, tumor microemboli, the Milan and UCSF criteria were found to be independent risk factors for RFS. In LT for HCC beyond the Milan criteria, a significant decrease in RFS was found in the IRF-1 negative groups. In SK-Hep1 cells, an increase in apoptosis and decrease in autophagy were observed after IFN-gamma stimulation, which was accompanied with increasing IRF-1 levels. When IRF-1 siRNA or a caspase inhibitor were used, reductions in LC3-II were diminished or disappeared after IFN-gamma stimulation, suggesting that IFN-gamma inhibited autophagy via IRF-1 expression and caspase activation. However, after IRF-1 siRNA was introduced, a reduction in LC3-II was found. Thus basic expression of IRF-1 was also necessary for autophagy. IRF-1 may be used as a potential target for HCC treatment based on its capacity to affect apoptosis and autophagy. Ki-67 shows great promise for the prediction of HCC recurrence in LT and can be used as an aid in the selection of LT candidates.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 1 区 医学
小类 | 2 区 肿瘤学 3 区 细胞生物学
最新[2025]版:
JCR分区:
出版当年[2014]版:
Q1 ONCOLOGY Q1 CELL BIOLOGY
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2014版] 出版当年五年平均[2010-2014] 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者单位: [1]First Central Clinical College, Tianjin Medical University, Tianjin, P. R. China [2]Department of Transplantation, Tianjin First Central Hospital, Tianjin, P. R. China [3]Tianjin Key Laboratory of Organ Transplantation, Tianjin, P. R. China
共同第一作者:
通讯作者:
通讯机构: [1]First Central Clinical College, Tianjin Medical University, Tianjin, P. R. China [2]Department of Transplantation, Tianjin First Central Hospital, Tianjin, P. R. China [3]Tianjin Key Laboratory of Organ Transplantation, Tianjin, P. R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:817 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)